7JN Stock Chart & Stats
€0.03
-€0.02(-30.16%)
At close: 4:00 PM EST
€0.03
-€0.02(-30.16%)
Day’s Range― - ―
52-Week Range€0.02 - €0.10
Previous CloseN/A
Volume0.00
Average Volume (3M)3.00
Market Cap
€55.58M
Enterprise Value€46.23M
Total Cash (Recent Filing)€7.71M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Sep 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding705,103,760
10 Day Avg. Volume10
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.80
Price to Sales (P/S)0.00
P/FCF Ratio-4.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory & Trial ReadinessMHRA approval and a fully prepared TOPICAL protocol materially reduce regulatory and operational start-up risk, enabling near-term execution and a clear data timeline. Trial readiness accelerates the path to clinically meaningful readouts, improves partner visibility and shortens time-to-decision for licensing or further investment.
Strong Human Challenge Efficacy SignalRobust biomarker suppression in a controlled human challenge provides durable mechanistic validation of the drug’s CRS‑prevention hypothesis. Such clear target engagement de-risks translation to patient studies, strengthens the scientific case for partners and payers, and increases likelihood of efficient later‑stage development.
IP & Orphan ExclusivityOrphan designation plus a long patent family create structural commercial protections that enhance future pricing and partnership leverage. Extended exclusivity and patent coverage support durable ROI for partners, improve licensing economics and make future royalty streams and deal terms more attractive.
Bears Say
Pre‑revenue With Sustained LossesBeing pre‑revenue with multi‑year operating losses means the company must rely on external funding or partnerships to advance programs. Persistent negative profitability constrains internal reinvestment, increases dilution risk from future financings, and makes long‑term viability contingent on achieving clinical milestones.
Equity Erosion Reduces FlexibilityMaterial equity erosion weakens the balance sheet cushion and reduces non‑dilutive financing options. Even with low leverage, a smaller equity base limits negotiating power with partners, raises the need for dilutive raises ahead of value‑creating inflection points, and heightens vulnerability to execution setbacks.
Dependence On External PartnersStrategic reliance on external pharma partners for late‑stage development and commercialization transfers execution and commercial risk outside the company. Success therefore hinges on partner appetite and deal terms after early readouts, potentially delaying or constraining the capture of upside and increasing execution uncertainty.
Poolbeg Pharma Ltd. News
7JN FAQ
What was Poolbeg Pharma Ltd.’s price range in the past 12 months?
Poolbeg Pharma Ltd. lowest stock price was €0.02 and its highest was €0.10 in the past 12 months.
What is Poolbeg Pharma Ltd.’s market cap?
Poolbeg Pharma Ltd.’s market cap is €55.58M.
When is Poolbeg Pharma Ltd.’s upcoming earnings report date?
Poolbeg Pharma Ltd.’s upcoming earnings report date is Sep 08, 2026 which is in 67 days.
How were Poolbeg Pharma Ltd.’s earnings last quarter?
Poolbeg Pharma Ltd. released its earnings results on Apr 28, 2026. The company reported -€0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.006.
Is Poolbeg Pharma Ltd. overvalued?
According to Wall Street analysts Poolbeg Pharma Ltd.’s price is currently Overvalued.
Does Poolbeg Pharma Ltd. pay dividends?
Poolbeg Pharma Ltd. does not currently pay dividends.
What is Poolbeg Pharma Ltd.’s EPS estimate?
Poolbeg Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Poolbeg Pharma Ltd. have?
Poolbeg Pharma Ltd. has 705,103,760 shares outstanding.
What happened to Poolbeg Pharma Ltd.’s price movement after its last earnings report?
Poolbeg Pharma Ltd. reported an EPS of -€0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.5%.
Which hedge fund is a major shareholder of Poolbeg Pharma Ltd.?
Currently, no hedge funds are holding shares in DE:7JN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Poolbeg Pharma Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-44.05%
12-Months-Change
Fundamentals
Return on Equity
-55.47%
Trailing 12-Months
Asset Growth
-2.98%
Trailing 12-Months
Company Description
Poolbeg Pharma Ltd.
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company based in the United Kingdom, focused on developing treatments for infectious diseases. Its pipeline features several key programs: POLB 001, a p38 MAP Kinase inhibitor intended for severe influenza; POLB 002, a pioneering, in-licensed RNA-based immunotherapy administered intranasally to combat respiratory virus infections; and POLB 003, an intramuscular vaccine aimed at preventing Melioidosis. Beyond specific therapeutic candidates, Poolbeg also holds licensed access to advanced micro- and nanoencapsulation technology for an oral vaccine delivery system designed to stimulate gut immunity. The company further advances its research through an artificial intelligence-powered drug program. Additionally, Poolbeg is developing a biomarker platform to identify individuals at high risk of severe disease, alongside a model-derived vaccine discovery platform to pinpoint novel vaccine candidates. Incorporated in 2021, Poolbeg Pharma plc is headquartered in London.
Technical Analysis
ImmuPharma
―
Sareum Holdings
―
HemoGenyx Pharmaceuticals Plc
―
Open Orphan Plc
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---